Why Invest in MindWalk

Why Invest in MindWalk

  1. The pharmaceutical industry already trusts us. More than 3,000 completed antibody discovery programs and 19 of the top 20 global pharmaceutical companies as clients. More than 20 publicly disclosed partner drug programs have reached the clinic from discovery work performed by MindWalk scientists, with many more under confidentiality. Those relationships generate revenue now and are the foundation for growing ReefIQ and LensAI enterprise adoption.
  2. We built what AI drug discovery is missing. AI models cannot reason over disconnected biological data, and that is the critical challenge holding back AI-driven drug discovery. Proprietary HYFT® Technology solves it. ReefIQ™ provides the biological intelligence and orchestration that connect an organization’s entire body of discovery data into one biological context, and LensAI™ reasons over it to deliver answers. Any AI model can plug in. No one else does this at scale.
  3. Recurring software revenue has started. Commercial adoption of ReefIQ™ and LensAI™ is building a scalable, recurring software revenue base, with a recent multi-year Teva agreement as the first enterprise validation.
  4. We own a therapeutic pipeline, not just a platform. The same discovery engine that put more than 20 publicly disclosed partner programs into the clinic is now building MindWalk’s own proprietary drug candidates. Every program that advances gives shareholders a second path to value: licensing, strategic partnerships, milestone payments and royalties. Until now, that upside went to our partners. Now we keep it.
  5.  Significant Operating Leverage. The transition from traditional discovery services toward higher-margin software and licensing revenue offers the potential for meaningful improvements in profitability and scalability.
  6. Strong Financial Foundation. A binding commitment for a US$30 million credit facility with attractive terms provides financial flexibility to pursue its commercial strategy and long-term growth opportunities.Content.
Forward-Looking Statements
This page contains forward-looking statements within the meaning of applicable United States and Canadian securities laws, including statements regarding MindWalk’s business strategy, the expected adoption of ReefIQ™ and LensAI™, the potential for recurring software revenue, anticipated operating leverage and improvements in profitability, the development and monetization of MindWalk’s therapeutic pipeline, and the negotiation, closing and availability of the senior unsecured revolving credit facility. Words such as “expect,” “position,” “potential,” “opportunity,” “will,” “may,” “intend” and similar expressions identify forward-looking statements.
These statements reflect management’s current expectations and assumptions as of the date they are made and are subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially, including: MindWalk’s history of net losses and its ability to achieve or sustain profitability; market acceptance of ReefIQ™ and LensAI™ and the timing and size of enterprise agreements; competition from companies with greater resources; the risk that MindWalk and the lender do not negotiate and execute a definitive credit agreement, or that conditions to closing or drawing are not satisfied; MindWalk’s ability to service or repay amounts drawn; the outcome and timing of therapeutic programs and partnering discussions; dependence on key customers and personnel; protection of intellectual property; and the other risks described under “Risk Factors” in MindWalk’s most recent Annual Report on Form 20-F and subsequent reports filed with the U.S. Securities and Exchange Commission and Canadian securities regulators, available at www.sec.gov and www.sedarplus.ca.
Forward-looking statements are not guarantees of future performance. Past success of partner programs originating from MindWalk discovery work does not ensure clinical or commercial success of any current or future program. References to partner programs reflect publicly disclosed programs only. MindWalk undertakes no obligation to update any forward-looking statement except as required by law.
Financial figures are presented in Canadian dollars unless otherwise indicated. HYFT® is a registered trademark of MindWalk Holdings Corp. LensAI™ and ReefIQ™ are trademarks of MindWalk Holdings Corp. or its subsidiaries; ReefIQ™ registration is pending.